Search Videos and More
Video
Marlise Luskin, MD, MSCE discusses results of a phase 1 trial
Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial
Video
Andrew A. Lane, MD, PhD discuss results from a phase 2 Study
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)
Video
Reid W. Merryman, MD discusses results of a multicenter phase II trial
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma
Video
Jacqueline Garcia, MD discussed results from the Phase # VERONA study
Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacititine (Pbo+Aza) in patients with treatment-naive, intermediate and higher-risk Myelodysplastic Syndromes (HR-MDS)
Video
Shayna Sarosiek, MD discusses WM-NET 1 trial
Deep responses following treatment with Ioncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those with high risk, TP53-altered Waldenstrom macroglobulinemia.
Video
Maria Capilla Guerra, MD discusses rapid diagnosis of acute leukemia with integrated epigentic and genetic profiling
News
Twenty-Five Years of Progress in Cancer
As we close out the first quarter of the twenty-first century, it isn’t hard to notice how much the world has changed since the year 2000. Smartphones. Social media. Artificial intelligence.
News
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.
Document
Tip Sheet: Medication-Related Osteonecrosis of the Jaw
The Breast Oncology Center developed this reference for providers caring for patients with medication-related osteonecrosis of the jaw in November 2025.
Video
Erica Mayer, MD discusses results from TBCRC 56 study
Erica Mayer, MD, of Dana-Farber Cancer Institute shared results from TBCRC 56, showing presurgical treatment with a PARP inhibitor + anti-PD1 combo in patients with gBRCAm early triple-negative breast cancer resulted in a pCR rate of 50%. Further ongoing correlative work may identify the best candidates for this non-chemo approach.
Video
Paolo Tarantino, MD discusses the DATO - Base study
Paolo Tarantino, MD, of Dana-Farber Cancer Institute, presented new findings from the DATO-Base study examining treatment with the ADC Dato-DXd for women with leptomeningeal disease. Breast cancer is the most common cancer linked to this rare but serious condition.
Video
Rachel Freedman, MD discusses phase 2 ATOP study
Dana-Farber Cancer Institute's Rachel Freedman, MD, presents results from the phase 2 ATOP study showing older patients with HER2+ breast cancer receiving adjuvant T-DM1 had a favorable 5-year survival with manageable toxicity. ATOP is the 1st adjuvant trial for older patients with HER2+ breast cancer in the United States.